Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy

Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy

Source: 
Fierce Pharma
snippet: 

The FDA on Friday gave Vyloy (zolbetuximab) the thumbs-up as a first-line treatment for adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2 positive.